PMC:7283670 / 64114-64292 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T368","span":{"begin":48,"end":56},"obj":"Disease"},{"id":"T369","span":{"begin":57,"end":66},"obj":"Disease"},{"id":"T370","span":{"begin":97,"end":105},"obj":"Disease"},{"id":"T371","span":{"begin":106,"end":115},"obj":"Disease"}],"attributes":[{"id":"A368","pred":"mondo_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A369","pred":"mondo_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A370","pred":"mondo_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A371","pred":"mondo_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T588","span":{"begin":127,"end":129},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T169","span":{"begin":172,"end":177},"obj":"Chemical"}],"attributes":[{"id":"A169","pred":"chebi_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:"}

{"project":"LitCovid-sentences","denotations":[{"id":"T643","span":{"begin":0,"end":178},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T222","span":{"begin":57,"end":66},"obj":"Phenotype"},{"id":"T223","span":{"begin":106,"end":115},"obj":"Phenotype"}],"attributes":[{"id":"A222","pred":"hp_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A223","pred":"hp_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1898","span":{"begin":34,"end":42},"obj":"Species"},{"id":"2131","span":{"begin":48,"end":66},"obj":"Disease"},{"id":"2132","span":{"begin":97,"end":115},"obj":"Disease"}],"attributes":[{"id":"A1898","pred":"tao:has_database_id","subj":"1898","obj":"Tax:9606"},{"id":"A2131","pred":"tao:has_database_id","subj":"2131","obj":"MESH:C000657245"},{"id":"A2132","pred":"tao:has_database_id","subj":"2132","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:"}